MONTEGO BAY, Jamaica, May 12, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness” or “the Company”), a leading global psychedelics company, has announced its expansion of psilocybin and ketamine product and retreat offerings to include 5-MeO-DMT through a partnership with Kaivalya Kollectiv, an L.A.-based wellness company. Kaivalya Kollectiv conducts psychedelic-integrated spiritual coaching and facilitated retreats in Mexico, Jamaica, and Costa Rica. Silo Wellness will operate two 5-MeO-DMT retreats in Jamaica, in addition to its existing psilocybin-assisted retreats and mushroom and truffle cultivation workshops. The Company will also continue testing its patent-pending nasal spray in Jamaica.
5-MeO-DMT, also known as the “God molecule” or “The Toad,” is a research chemical psychedelic belonging to the tryptamine class. It is four to six times more potent than DMT (N,N-dimethyltryptamine), a better-known psychedelic. 5-MeO-DMT shows promise in treating certain medical conditions, improving well-being and mindfulness, and reducing symptoms of psychological disorders with a single inhalation.
Douglas K. Gordon, Chief Executive Officer of Silo Wellness, stated, “Psychedelic experiences can be profoundly transformative and deeply healing. We are pleased to expand our portfolio to include 5-MeO-DMT retreats, especially at a time when so many people are struggling with mental health issues and looking for plant-based alternatives to help guide them on their paths to greater self-actualization.”
Silo Wellness and Kaivalya Kollectiv will integrate the 5-MeO-DMT experience into two new Jamaican retreats, featuring yoga, meditation, breathwork, spiritual coaching, and unique culinary and cultural experiences. This partnership marks the first time a publicly traded company offers a 5-MeO-DMT wellness retreat and the first of its kind to be held in Jamaica.
5-MeO-DMT is naturally found in various plants, certain toad species, and can also be produced synthetically. It induces hallucinogenic experiences lasting between 7 and 90 minutes and has long been used by indigenous communities as a healing modality. Today, 5-MeO-DMT, along with other psychedelic compounds like psilocybin and ketamine, is gaining mainstream popularity due to clinical trials, formal research proving its efficacy as a mental health tool, and advocacy initiatives working towards decriminalization and regulation.
For more information about Silo Wellness psychedelic retreats or to register, please visit https://www.silowellness.com/retreats. Registration is subject to screening and approval by facilitators. It’s important to note that no medical treatment or psychotherapy is offered or available at any retreat, and the retreats do not claim to cure or mitigate any physical or mental diseases, symptoms, disorders, or abnormalities.
ABOUT SILO WELLNESS
Silo Wellness aims to improve health and wellness by developing and introducing psychedelic medicine to reduce trauma and enhance performance. The company focuses on destigmatizing active compounds in psychedelics, innovating ease of administration and ingestion, and introducing new, safe, and affordable alternatives to current medicines. Silo Wellness conducts ketamine and psilocybin wellness retreats, manufactures and distributes functional mushrooms, and has been involved in the development of psilocybin-free functional mushroom tinctures and a psilocybin nasal spray formulation in Jamaica. The company does not claim that its products cure or mitigate any physical or mental diseases, symptoms, disorders, or abnormalities.
ABOUT KAIVALYA KOLLECTIV
Kaivalya Kollectiv is a retreat company that specializes in psychedelic wellness, particularly 5-MeO-DMT. By combining ancient eastern and indigenous practices with modern science and Western therapies, Kaivalya Kollectiv aims to draw on ancient roots for modern growth. The company’s focus areas include psychedelics/plant medicine, Western and Eastern therapy, biotech and research, and yoga/meditation and breathwork.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements based on expectations, estimates, and projections as of the date of this news release. These statements involve discussions regarding predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events, or performance. Forward-looking statements are not statements of historical fact and may be identified by phrases such as “expects,” “does not expect,” “is expected,” “anticipates,” “does not anticipate,” “plans,” “budget,” “scheduled,” “forecasts,” “estimates,” “believes,” or “intends,” or variations of such words and phrases, or stating that certain actions, events, or results “may” or “could,” “would,” “might,” or “will” be taken or occur. These forward-looking statements relate to the operations and efficacy of the Company’s retreats in Oregon and Jamaica, the offering of 5-MeO-DMT retreats, the partnership with Kaivalya Kollectiv, research and decriminalization of psychedelic compounds, and the business plans of Silo Wellness. They are based on a number of estimates and assumptions considered reasonable but are subject to known and unknown risks, uncertainties, and other factors that may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to, general business, economic, competitive, political, and social uncertainties, as well as the potential impact of COVID-19. There can be no assurance that the forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update forward-looking statements unless required by law. Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release.